The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.
 
Rob C. Stein
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - Teva
 
Andreas Makris
Honoraria - Lilly; NanoString Technologies; Pfizer; Roche
Consulting or Advisory Role - Lilly; Pfizer; Roche
Speakers' Bureau - Lilly; NanoString Technologies; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Iain R. MacPherson
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis Pharmaceuticals UK Ltd.; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo; Novartis Pharmaceuticals UK Ltd.; Pfizer; Roche
Travel, Accommodations, Expenses - Eisai
 
Luke Hughes-Davies
No Relationships to Disclose
 
Andrea Marshall
No Relationships to Disclose
 
Georgina Dotchin
No Relationships to Disclose
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis
 
Belinda Emma Kiely
Honoraria - Novartis
Consulting or Advisory Role - Roche
 
Janice Tsang
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Novartis; Pfizer
 
Bjørn Naume
No Relationships to Disclose
 
Daniel William Rea
Honoraria - daiiachi Sankyo; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Genomic Health; MSD Oncology
Research Funding - bioTheranostics (Inst); Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer
 
Hege Oma Ohnstad
No Relationships to Disclose
 
Peter S Hall
Consulting or Advisory Role - Daiichi-Sanchyo (Inst); Flatiron Health (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Stuart McIntosh
Honoraria - Roche
Consulting or Advisory Role - Roche
Speakers' Bureau - Daiichi Sankyo
Research Funding - Novartis
Travel, Accommodations, Expenses - Roche
 
Bethany Shinkins
Research Funding - PinPoint Data Science (Inst)
 
Chris McCabe
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
 
Adrienne Morgan
No Relationships to Disclose
 
John Bartlett
Honoraria - bioTheranostics; NanoString Technologies; Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Insight Genetics; oncoXchange; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019; John Bartlett currently has 5 pending patents: 1. Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned 2. Jan 2017: Systems, Devices and Methods for Constructi (Inst)
Travel, Accommodations, Expenses - bioTheranostics; NanoString Technologies
 
Janet Dunn
No Relationships to Disclose